A Phase 2 interventional study of Naloxone Hydrochloride and Fentanyl in Fentanyl Overdose and Fentanyl Poisoning, sponsored by Clear Scientific, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Clear Scientific, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Poisoning with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Poisoning · United States.
Among the 14 studies in Poisoning with a site in United States, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2, and was the 14th registered.
98 studies on the registry are indexed under Poisoning; 16 are open to participants now.
Browse Poisoning studies →1 of the 14 studies in Poisoning with a site in United States is open now. Recruiting first, the newest first:
Anova Enterprises, Inc · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Poisoning studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2026.
This study's enrollment of 16 is below the median of 46 across 52 interventional studies indexed under Poisoning.
Median enrollment 16 across the 11 interventional studies, 1,000 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Clear Scientific, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Clear Scientific, Inc. has 1 study filed under Poisoning — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Poisoning with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CS-1103 (1,000 mg), given by intravenous (IV) infusion in healthy participants in the presence of a clinically relevant dose of fentanyl (200 μg, IV), with naloxone blockade (400 μg, IV).
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive naloxone blockade (400 μg, IV), followed by fentanyl (200 μg, IV), followed by placebo (saline).
Drug: Naloxone Hydrochloride · Drug: Fentanyl · Drug: Sterile Saline
Participants receive naloxone blockade (400 μg, IV), followed by fentanyl (200 μg, IV), followed by CS-1103 (1,000 mg, IV).
Drug: Naloxone Hydrochloride · Drug: Fentanyl · Drug: CS-1103
Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinations
Physical examinations
Time frame: 3 days plus follow-up on Day 10
Number of participants with CS-1103-related adverse events (AEs) assessed by electrocardiograms (ECGs)
Digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted
Time frame: 3 days plus follow-up on Day 10
Number of participants with CS-1103-related adverse events (AEs) assessed by vital signs
Blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature
Time frame: 3 days plus follow-up on Day 10
Number of participants with CS-1103-related adverse events (AEs) assessed by laboratory parameters
Clinical chemistry, hematology, coagulation, and urinalysis
Time frame: 3 days plus follow-up on Day 10
Time course of CS-1103 blood and urine concentrations
Measurement of plasma and urine concentrations of CS-1103
Time frame: 48 hours
Time course and magnitude of urine excretion of fentanyl
Measurement of concentration of fentanyl in urine
Time frame: 48 hours
Effect of CS-1103 and fentanyl on QT interval
Concentration-QT correlation performed on baseline-corrected QTcF time-matched with PK for fentanyl and CS-1103 in plasma
Time frame: 48 hours
Effect of CS-1103 on the naloxone plasma and urine PK, if any
Measurement of standard urine and plasma PK parameters between placebo and CS-1103 treated participants
Time frame: 48 hours
Ran from May 2026 to primary completion in Jul 2026, 1 month.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jul 2026, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CS-1103
Clear Scientific, Inc.